Bartlett & CO. Wealth Management LLC Has $1.08 Million Position in Cencora, Inc. (NYSE:COR)

Bartlett & CO. Wealth Management LLC grew its stake in Cencora, Inc. (NYSE:COR) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,826 shares of the company’s stock after buying an additional 100 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Cencora were worth $1,084,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in COR. Public Sector Pension Investment Board increased its position in Cencora by 39.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 4,508 shares of the company’s stock valued at $1,016,000 after purchasing an additional 1,274 shares during the period. Evergreen Capital Management LLC boosted its stake in shares of Cencora by 4.7% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company’s stock valued at $258,000 after purchasing an additional 52 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Cencora during the second quarter worth $1,539,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Cencora by 68.8% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 34,386 shares of the company’s stock worth $7,747,000 after buying an additional 14,017 shares during the last quarter. Finally, AXA S.A. lifted its holdings in Cencora by 47.0% in the second quarter. AXA S.A. now owns 251,781 shares of the company’s stock valued at $56,726,000 after buying an additional 80,540 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

COR opened at $247.84 on Friday. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $253.27. The company has a market cap of $47.90 billion, a price-to-earnings ratio of 33.00, a PEG ratio of 1.53 and a beta of 0.49. The company’s fifty day moving average price is $237.26 and its two-hundred day moving average price is $234.40. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.89%. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Analyst Upgrades and Downgrades

COR has been the subject of several research analyst reports. Leerink Partners lowered their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Barclays lifted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Evercore ISI lifted their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Mizuho assumed coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.60.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,187 shares of company stock worth $17,790,912. Insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.